Yoshida Y, Matsuda K, Sasaki H, Matsumoto Y, Matsumoto S, Tawara S, Takasugi H. Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879.
Bioorg Med Chem Lett 2004;
14:2627-31. [PMID:
15109666 DOI:
10.1016/j.bmcl.2004.02.068]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2003] [Accepted: 02/17/2004] [Indexed: 10/26/2022]
Abstract
The synthesis, therapeutic efficacy against H. pylori, and preliminary safety of the novel cephem derivative, FR193879 (8a) are described. Compound 8a having a (4-carbamoylmethylthiazol-2-yl)thio moiety at the 3-position and a phenylacetamido at the 7-position was found to have good safety showing a nontoxic dose of > 100 mg/kg in dogs in a 4-week repeat dose toxicity study and extremely potent therapeutic efficacy against H. pylori, showing 30 times superior activity compared to AMPC, and did not display cross-resistance with CAM or MNZ.
Collapse